NCT07218003 - A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | Biotech Hunter

Enrollment

149

Participants

Timeline

Start Date

October 27, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

March 31, 2029

Conditions

Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell CancerTriple Negative Breast Cancer (TNBC)Urothelial Carcinoma BladderGastroesophageal Junction (GEJ) AdenocarcinomaEsophageal Squamous Cell CancerGastric CancerCancerSolid Tumors (Phase 1)

Interventions

DRUG

RNDO-564

CD28 x Nectin-4 bispecific

DRUG

Pembrolizumab

Anti-PD-1 therapy

Trial Locations (2)

28078

Carolina Biooncology, Huntersville

37203

Sarah Cannon Research Institute, LLD, Nashville